数据显示，我国前列腺癌年新发病例13.42万，在男性泌尿生殖系统肿瘤中位列首位，且发病率与死亡 率仍逐年增长，成为威胁中老年男性身心健康的重要疾病之一。龚侃教授表示，前列腺癌的发病风险随 着年龄的增长逐渐升高，规范筛查PSA往往是对抗前列腺癌的警戒线，"建议50岁以上男性定期进行 PSA检测，存在前列腺癌家族史的男性需提前至45岁，争取尽早发现、尽早干预。"目前，规范的PSA 筛查已经使越来越多的早期前列腺癌患者实现临床治愈，但由于前列腺癌早期症状隐匿、社会早筛意识 有待进一步提升，我国前列腺癌患者确诊时已出现远处转移的比例超过30%，整体预后较差。"如何有 效控制晚期患者的疾病进展，延长患者生存期，始终是医学界探索的核心方向"，龚侃教授指出，近年 来新型内分泌治疗药物、靶向药物等创新治疗方案的问世，正在让患者的生存期不断突破，显著改善患 者预后。 在晚期前列腺癌的治疗评估中，PSA的深度速降则是良好预后的关键"信号灯"，"在评估治疗效果时， 我们不仅要看PSA是否下降，还要看PSA是否在早期就实现了快速、深度的下降。研究表明，接受新型 内分泌治疗的患者若在3个月内PSA水平迅速降至0.2ng/mL以下，其无 ...

Core Insights - The incidence of prostate cancer in China is rapidly increasing, posing a significant threat to men's health [1] - Early detection through scientific screening and standardized treatment can lead to long-term high-quality survival for patients [1][2] Group 1: Screening and Diagnosis - Prostate cancer early symptoms are often subtle and similar to benign conditions, making standardized screening crucial [1] - PSA (Prostate-Specific Antigen) testing is currently the most effective screening method [1] - The optimal screening age is between 50 to 75 years, with those having a family history advised to start screening at 45 [1] Group 2: Treatment Advances - Recent advancements in treatment methods for prostate cancer have significantly improved patient outcomes [1] - New endocrine therapy drugs have extended the median overall survival for metastatic hormone-sensitive prostate cancer patients to over 8 years, surpassing traditional medications [1] - The application of targeted and radionuclide therapies further benefits survival for late-stage patients [1] Group 3: Quality of Life and Rehabilitation - Prostate cancer treatment should focus not only on extending survival but also on enhancing the quality of life [2] - Post-surgery rehabilitation, particularly pelvic floor muscle training, is crucial for improving urinary incontinence issues [2] - A multidisciplinary approach to managing bone metastasis has shown significant effectiveness in alleviating pain and preventing fractures [2] Group 4: Public Awareness and Prevention - Prostate cancer is transitioning from a high-mortality tumor to a manageable chronic disease through scientific screening and comprehensive management [2] - There is a need for increased public awareness regarding cancer prevention and the importance of proactive screening [2]

Core Viewpoint - The news highlights the controversy surrounding former President Biden's cancer diagnosis, raising questions about transparency and the implications for his political legacy and future elections [1][5]. Group 1: Public Reaction and Political Implications - Trump's camp has expressed surprise at the delayed disclosure of Biden's cancer diagnosis, questioning the honesty of Biden's medical team and suggesting that Biden may not have been fit to serve during his presidency [2][3]. - Biden's health issues are seen as a potential liability for the Democratic Party, affecting upcoming elections and the party's credibility [5]. Group 2: Medical Community's Concerns - Medical experts have raised doubts about the adequacy of Biden's health screenings, suggesting that his cancer diagnosis may have been known for a longer period than publicly acknowledged [4]. - The lack of recent prostate cancer screenings for Biden has been criticized, with experts indicating that regular health checks are essential for someone in his position [4]. Group 3: Democratic Party's Internal Dilemmas - There is growing concern among Democratic leaders regarding Biden's ability to lead effectively, with some questioning the timing of his cancer diagnosis and its implications for future elections [5]. - The party faces challenges in reconciling Biden's health issues with his political achievements, potentially impacting voter support [5].

Core Viewpoint - The article discusses the recent diagnosis of prostate cancer in former US President Joe Biden, highlighting the implications of prostate cancer screening policies in the US and the importance of early detection [3][4][9]. Group 1: Biden's Diagnosis - Joe Biden was diagnosed with aggressive prostate cancer that has metastasized to his bones, with a Gleason score of 9 and stage 4 classification, indicating late-stage cancer [3][4]. - Biden's case raises questions about the effectiveness of routine health screenings, particularly the PSA test, which has been used for prostate cancer screening since 1991 [3][9]. Group 2: Prostate Cancer Screening Guidelines - The American Cancer Society recommends that men discuss the potential benefits and risks of prostate cancer screening with their doctors, starting at age 50 for average-risk individuals and at age 45 for high-risk groups [9][10]. - PSA levels are used to detect prostate cancer, but elevated levels can also result from benign conditions, complicating the diagnosis [11][13]. Group 3: Screening Recommendations and Risks - The article outlines that men with a PSA level of 2.5 ng/mL or higher should be re-evaluated annually, while those with lower levels should be checked every two years [14]. - The potential negative effects of widespread PSA screening include false positives, overdiagnosis, and overtreatment, which can lead to unnecessary anxiety and complications [16][17][18]. Group 4: Prostate Cancer Statistics in China - In 2022, approximately 134,200 new cases of prostate cancer were reported in China, making it the sixth most common male malignancy, with 47,500 deaths [27]. - The incidence and mortality rates of prostate cancer in urban areas of China have been rising, indicating a growing public health concern [27]. Group 5: Treatment Options - Treatment for advanced prostate cancer, such as Biden's case, typically involves androgen deprivation therapy (ADT), which aims to reduce testosterone levels to slow cancer growth [28]. - Despite advancements in treatment, prognosis is influenced by various factors, including the extent of the disease at diagnosis, with early detection significantly improving survival rates [28].